AIDA'S SUBSIDIARY TO BEGIN ANTITUMOR DRUG TRIALS

Aida Pharmaceuticals announced that its subsidiary, Shanghai Qiaer Biotechnology, has formally begun the large-scale Phase II trials of Rh-Apo2L throughout mainland China.

The companies received approval from the State Food and Drug Administration to begin trials of Rh-Apo2L in December of last year, making Rh-Apo2L the first and only anticancer therapy of its kind in the world to be approved for Phase II clinical trials, according to Aida.

The trials will analyze the effect of Rh-Apo2L on the following cancers: advanced inert lymphoma, malignant melanoma, soft tissue sarcoma, pancreatic cancer, kidney cancer, non-small-cell lung cancer and colorectal cancer. The trials will analyze the specific efficacy of Rh-Apo2L in more than 100 patients. Additionally, the company will continue to analyze the dosage and effectiveness of the drug as well as other drugs' interactions with Rh-Apo2L.

Rh-Apo2L is a broad-spectrum genetic cell apoptosis agent that the company expects to be useful for the treatment of a variety of cancerous tumors.